Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Study Overview: Regeneron Pharmaceuticals, in collaboration with Bayer, has completed an extension study titled An Extension Study to Evaluate the Long-term Outcomes of Subjects Who Received Treatment for Retinopathy of Prematurity in Study 20090. The study aims to assess the long-term effects of treatments administered in the FIREFLEYE study, focusing on the condition known as Retinopathy of Prematurity (ROP), a serious eye disorder affecting premature infants.

Intervention/Treatment: The study evaluated two interventions previously administered in Study 20090: the drug Eylea (Aflibercept) and a procedure called Laser photocoagulation. Eylea is an injectable solution designed to treat eye conditions, while Laser photocoagulation is a laser therapy used to prevent retinal detachment.

Study Design: This Phase 3 interventional study followed a non-randomized, parallel assignment model with no masking. Its primary purpose was to observe the long-term outcomes of the treatments, rather than to administer new ones.

Study Timeline: The study was first submitted on June 28, 2019, and the last update was submitted on October 9, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data collection and analysis.

Market Implications: The completion of this study could positively impact Regeneron Pharmaceuticals’ stock performance by reinforcing the efficacy and safety profile of Eylea, potentially increasing its market share in the treatment of ROP. This update may also influence investor sentiment, as successful long-term outcomes can enhance the company’s reputation in the ophthalmology sector, where competition is intense.

The study is confirmed as completed, with further details available on the ClinicalTrials portal.